Form 4: Cryo Cell International Co-CEO Mark Portnoy Reports Acquisition of Stock Options
SEC Form 4 Filing
Mark Portnoy, Co-CEO of Cryo Cell International, reports the acquisition of 25,000 stock options.
Summary
- Mark L. Portnoy, Co-CEO of Cryo Cell International Inc. (CCEL), filed a Form 4 with the SEC.
- The filing reports the acquisition of 25,000 stock options on January 21, 2025, at an exercise price of $8.08.
- These options vest in three tranches: 1/3 upon issuance, 1/3 on January 21, 2026, and 1/3 on January 21, 2027.
- The options expire on January 21, 2030.
- Portnoy also directly owns 821,973 shares of common stock.
- He indirectly owns 42,266 shares through a 401K and 71,529 shares through a partnership.
Sentiment
Score: 6
Explanation: Neutral sentiment. The filing is a standard disclosure of stock option acquisition. The acquisition itself could be seen as a positive signal, but the filing is primarily informational.
Positives
- The acquisition of stock options by the Co-CEO could be interpreted as a sign of confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. They are closely watched by investors for signals about management's confidence in the company's prospects.
Stakeholder Impact
- The acquisition of stock options by a top executive can influence investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/30/2019 | Date of previously granted stock options with an exercise price of $7.53 and an expiration date of 08/30/2029. |
| 12/20/2019 | Date of previously granted stock options with an exercise price of $7.28 and an expiration date of 12/20/2029. |
| 12/22/2021 | Date of previously granted stock options with an exercise price of $12.27 and an expiration date of 12/22/2028. These options vest immediately if the share price reaches $25.00. |
| 12/23/2022 | Date of previously granted stock options with an exercise price of $4.3 and an expiration date of 12/23/2027. |
| 01/03/2023 | Date of previously granted stock options with an exercise price of $4.77 and an expiration date of 01/03/2028. Vesting schedule is detailed in the explanation. |
| 12/22/2023 | Date of previously granted stock options with an exercise price of $6.47 and an expiration date of 12/22/2028. Vesting schedule is detailed in the explanation. |
| 01/21/2025 | Date of transaction: Mark Portnoy acquired 25,000 stock options at $8.08 each, exercisable until 01/21/2030. Vesting schedule is detailed in the explanation. |
| 01/23/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.